1. Home >
  2. M&A >
  3. Divestiture >
  4. Canada >
  5. Manitoba >
  6. Liminal BioSciences Acquires Emergent BioSolutions - Plasma Collection Facility

M&A Deal Summary

Liminal BioSciences Acquires Emergent BioSolutions - Plasma Collection Facility

On May 28, 2015, Liminal BioSciences acquired life science company Emergent BioSolutions - Plasma Collection Facility from Emergent BioSolutions

Acquisition Highlights
  • This is Liminal BioSciences’ 1st transaction in the Life Science sector.
  • This is Liminal BioSciences’ 1st transaction in Canada.
  • This is Liminal BioSciences’ 1st transaction in Manitoba.

M&A Deal Summary
Date 2015-05-28
Target Emergent BioSolutions - Plasma Collection Facility
Sector Life Science
Buyer(s) Liminal BioSciences
Sellers(s) Emergent BioSolutions
Deal Type Divestiture

Target

Emergent BioSolutions - Plasma Collection Facility

Winnipeg, Manitoba, Canada
Emergent’s plasma collection center is an FDA and Health Canada licensed plasma collection facility. The plasma collection center is conveniently located in close proximity to the existing Emergent Winnipeg based cGMP manufacturing facility, which was recently announced as providing ProMetic with up to 250,000 liters of annual plasma processing capacity.

Search 205,905 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Liminal BioSciences

Laval, Quebec, Canada
Category Company
Founded 1994
Sector Life Science
Employees251
Revenue 1M CAD (2021)
DESCRIPTION

Liminal BioSciences is a biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics, and small-molecule drug development. The Company offers its state-of-the-art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics. Liminal BioSciences was founded in 1994 and is based in Laval, Canada.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 1
State (Manitoba) 1 of 1
Country (Canada) 1 of 2
Year (2015) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-24 Telesta Therapeutics

Saint-Laurent, Quebec, Canada

Telesta Therapeutics, Inc. is a clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company’s anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.

Buy -

Seller(S) 1

SELLER

Emergent BioSolutions

Gaithersburg, Maryland, United States
Category Company
Founded 1998
Sector Healthcare Services
Employees1,600
Revenue 1.0B USD (2023)
DESCRIPTION

Emergent BioSolutions is a specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Emergent BioSolutions was founded in 1998 and is based in Gaithersburg, Maryland.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 2
State (Manitoba) 1 of 1
Country (Canada) 1 of 1
Year (2015) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-12-17 Evolva Holding - EV-035

Switzerland

EV-035 is a series of novel small molecule broad spectrum antibiotics of the 4-oxoquinolizine class and targets bacterial type IIa topoisomerase.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-07-19 GlaxoSmithKline - Raxibacumab

Brentford, United Kingdom

GlaxoSmithKline plc - Raxibacumab is an indicated for the treatment of adult and pediatric patients with inhalational anthrax in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or not appropriate.

Buy $130M
Mergr

Product

Company

Legal